疫苗接种与妊娠期COVID-19母婴结局的关系
该研究基于CANCOVID-Preg数据库,对2021年4月5日至2022年12月31日期间加拿大9个省份/地区感染SARS-CoV-2的孕妇进行人群水平监测,共纳入19899例符合分析条件的病例。其中72%在COVID-19诊断前已接种疫苗,28%未接种。接种疫苗与较低的住院风险(Delta变异株时期RR 0.38,Omicron时期RR 0.38)、重症监护入住风险(Delta RR 0.10,Omicron RR 0.10)和早产风险(Delta RR 0.80,Omicron RR 0.64)相关。多变量分析控制合并症后,接种疫苗仍与较低住院风险相关。结论认为,妊娠前及妊娠期间接种SARS-CoV-2疫苗与较低的严重孕产妇疾病和早产风险相关,且不受变异株时期影响。
要点
- 在19899例妊娠期SARS-CoV-2感染病例中,72%在诊断前已接种疫苗,28%未接种。
- 接种疫苗与住院风险降低相关:Delta时期RR 0.38(95%CI 0.30-0.48),Omicron时期RR 0.38(95%CI 0.27-0.53)。
- 接种疫苗与重症监护入住风险降低相关:Delta时期RR 0.10(95%CI 0.04-0.26),Omicron时期RR 0.10(95%CI 0.03-0.29)。
- 接种疫苗与早产风险降低相关:Delta时期RR 0.80(95%CI 0.66-0.98),Omicron时期RR 0.64(95%CI 0.52-0.77)。
- 多变量分析控制合并症后,接种疫苗仍与较低住院风险相关;Omicron时期未接种者调整后住院RR为2.43(95%CI 1.72-3.43),Delta时期为3.82(95%CI 2.38-6.14)。
适用人群与场景
- 2021年4月5日至2022年12月31日期间在加拿大9个省份/地区诊断COVID-19的孕妇及其婴儿。
- 纳入标准:妊娠期SARS-CoV-2感染,无论是否在诊断前接种疫苗。
研究设计与关键结果
- 研究类型:基于CANCOVID-Preg数据库的人群水平监测;共识别26584例,其中19899例符合分析条件。
- 人群特征:多数感染发生于30至35岁(46.3%)和白人种族(55.9%);72%(n=14367)在COVID-19诊断前已接种疫苗,28%(n=5532)未接种;已接种者中80%(n=11425)在妊娠前接种,20%(n=2942)在妊娠期间接种。
- 变异株时期:Delta时期病例n=6120,Omicron时期病例n=13799。
- 住院风险:Delta时期接种组vs未接种组RR 0.38(95%CI 0.30-0.48),ARD 8.7%(95%CI 7.3%-10.2%);Omicron时期RR 0.38(95%CI 0.27-0.53),ARD 3.8%(95%CI 2.4%-5.2%)。
- 重症监护入住风险:Delta时期RR 0.10(95%CI 0.04-0.26),ARD 2.4%(95%CI 1.8%-2.9%);Omicron时期RR 0.10(95%CI 0.03-0.29),ARD 0.85%(95%CI 0.27%-1.44%)。
- 早产风险:Delta时期RR 0.80(95%CI 0.66-0.98),ARD 1.8%(95%CI 0.3%-3.4%);Omicron时期RR 0.64(95%CI 0.52-0.77),ARD 4.1%(95%CI 2.0%-6.2%)。
- 多变量分析:控制合并症后,接种疫苗仍与两个变异株时期较低的住院风险相关;Omicron时期未接种组调整后住院RR 2.43(95%CI 1.72-3.43),Delta时期未接种组调整后住院RR 3.82(95%CI 2.38-6.14)。
证据类型、等级与局限
- 证据类型:基于CANCOVID-Preg数据库的人群水平监测(观察性研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,妊娠前及妊娠期间接种SARS-CoV-2疫苗与较低的严重孕产妇疾病和早产风险相关,且不受变异株时期影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Gaps in knowledge exist about the impact of COVID-19 and vaccination on pregnancy outcomes.
OBJECTIVE: To investigate the impact of vaccination on maternal and perinatal outcomes associated with SARS-CoV-2 infection in pregnancy.
DESIGN, SETTING, AND POPULATION: Population-level surveillance of pregnant individuals infected with SARS-CoV-2 and their infants using the CANCOVID-Preg database between April 5, 2021 (beginning of the Delta variant time period and initiation of recommendations for vaccination in pregnancy in Canada), and December 31, 2022. Cases were identified based on COVID-19 diagnoses in pregnancy in 9 of 13 Canadian provinces/territories. Cases occurring through 2022 were followed up into 2023 for pregnancy conclusion and infant outcomes.
EXPOSURE: SARS-CoV-2 infection in pregnancy, with or without prior vaccination.
MAIN OUTCOMES AND MEASURES: COVID-19-associated hospitalization, critical care unit admission, and preterm birth.
RESULTS: Of 26 584 cases identified, 19 899 cases were eligible for analysis. Among these, most infections occurred among those aged 30 to 35 years (46.3%) and among those of White race (55.9%). A total of 72% (n = 14 367) of cases were vaccinated and 28% (n = 5532) were unvaccinated prior to their COVID-19 diagnosis. Among those vaccinated prior to COVID-19 diagnosis, 80% (n = 11 425) were vaccinated prior to pregnancy and 20% (n = 2942) were vaccinated during pregnancy. Cases occurred during both Delta (n = 6120) and Omicron (n = 13 799) variant time periods. Vaccination was associated with lower risk of hospitalization (Delta: relative risk [RR], 0.38 [95% CI, 0.30-0.48]; absolute risk difference [ARD], 8.7% [95% CI, 7.3%-10.2%]; Omicron: RR, 0.38 [95% CI, 0.27-0.53]; ARD, 3.8% [95% CI, 2.4%-5.2%]), critical care unit admission (Delta: RR, 0.10 [95% CI, 0.04-0.26]; ARD, 2.4% [95% CI, 1.8%-2.9%]; Omicron: RR, 0.10 [95% CI, 0.03-0.29]; ARD, 0.85% [95% CI, 0.27%-1.44%]), and preterm birth (Delta: RR, 0.80 [95% CI, 0.66-0.98]; ARD, 1.8% [95% CI, 0.3%-3.4%]; Omicron: RR, 0.64 [95% CI, 0.52-0.77]; ARD, 4.1% [95% CI, 2.0%-6.2%]). In multivariable analyses, vaccination was still associated with lower hospitalization risk in both variant time periods after controlling for comorbid conditions. In Omicron, compared with the vaccinated group, those unvaccinated had an adjusted RR of hospitalization of 2.43 (95% CI, 1.72-3.43). In Delta, those unvaccinated had an adjusted RR of hospitalization of 3.82 (95% CI, 2.38-6.14).
CONCLUSIONS AND RELEVANCE: Vaccination against SARS-CoV-2 prior to and during pregnancy, before COVID-19 diagnosis, was associated with a lower risk of severe maternal disease and preterm birth regardless of variant time period.
参考来源
- McClymont E, Blitz S, Forward L, et al. The Role of Vaccination in Maternal and Perinatal Outcomes Associated With COVID-19 in Pregnancy. JAMA. 2026. PMID: 41396589. doi:10.1001/jama.2025.21001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。